Reining In “March In”: NIH Rejects Xtandi Petition
This article was originally published in RPM Report
Executive Summary
The National Institutes of Health is rejecting calls to exercise “march in” rights on patents for a cancer drug, declaring its view that the authority is narrowly focused on shortages – not pricing.